Market Currents
Amgen (AMGN) says the FDA has approved a new indication for Prolia as a treatment to increase...
-
Thursday, September 20, 2012, 7:26 PM ETAmgen (AMGN) says the FDA has approved a new indication for Prolia as a treatment to increase bone mass in men with osteoporosis at high risk for fracture. Prolia is the first FDA-approved subcutaneous injection administered every six months. Studies of men with low bone mineral density who took the treatment resulted in significantly greater bone density gains when compared to a placebo.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
